Gapping up
In reaction to earnings/guidance:
- AMTD +6.7%, IDCC +2.4%
Select oil/gas related names showing strength:
- OIH +5%, BP +4.2%, USO +4%, HAL +4%, TTE +3.8%, SHEL +3.5%, XLE +3.3%, SLB +3.3%, PSX +3%, XOM +2.8%
Other news:
- MYOV +31.7% (confirms receipt of preliminary, non-binding proposal from Sumitovant Biopharma and Sumitomo Pharma to acquire remaining shares for $22.75 per share)
- CLVS +10.1% (Phase 3 trial of Rubraca achieves primary endpoint in men with metastatic castration-resistant prostate cancer with BRCA or ATM Mutations )
- LXRX +8.3% (reports new analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events)
- AXSM +7.6% (announces Sunosi meets primary endpoint)
- BCDA +7.2% (presents positive CardiAMP cell therapy heart failure trial two-year data at HFSA Annual Meeting)
- OMER +4.8% (announces royalty monetization transaction with DRI Healthcare Trust)
- ACTG +3.7% (provides update on strategic partnership with Starboard Value LP)
- RDW +2.9% (acquires QinetiQ Space NV)
- FLR +2.8% (awarded a $1.33 bln US Navy modification to previously awarded contract for Naval Nuclear Propulsion work)
- NOTE +2.8% (has acquired the core operating assets and book of business of DT-Global Business Consulting)
- FRPT +2.4% (trades +4% after hours on report co has hired bankers to explore a potential sale, according to Barron's)
- AQN +2.1% (to sell ownership interests in a portfolio of operating wind projects in the United States and Canada to InfraRed Capital Partners)
- BITF +1.9% (Provides September 2022 Production and Mining Operations Update)
- XOS +1.7% (files for 11,571,966 share common stock offering by selling shareholder)
- LMT +0.9% (increases its quarterly dividend 7.1% to $3.00/share)
- NIO +0.8% (Sep deliveries)
Analyst comments:
- BOX +3.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CF +2.8% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- WFC +1.4% (upgraded to Buy from Neutral at Goldman)